E11

Type 2 diabetes mellitus without complications

# Overview of Type 2 Diabetes Mellitus (T2DM) without Complications (ICD-10: E11.9) Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia (high blood glucose) resulting from either insulin resistance, insufficient insulin secretion by the pancreatic beta cells, or both. ICD-10 code E11.9 specifically identifies Type 2 diabetes mellitus when no specific complications (such as renal, ophthalmic, or neurological complications) have been documented or are present. This diagnosis often represents an early stage of the disease, a well-managed condition, or a presentation where complications have not yet manifested. ## Pathophysiology The primary pathophysiological defects in T2DM include insulin resistance and progressive beta-cell dysfunction. Initially, peripheral tissues (muscle, liver, adipose tissue) become resistant to the effects of insulin, meaning they require higher levels of insulin to take up glucose from the bloodstream. In response, the pancreatic beta cells compensate by increasing insulin production, leading to hyperinsulinemia. Over time, however, the beta cells become exhausted and lose their capacity to produce and secrete sufficient insulin, resulting in relative insulin deficiency. This dual defect leads to persistent hyperglycemia. Other contributing factors include increased hepatic glucose production, impaired incretin effect (reduced secretion or action of gut hormones like GLP-1 and GIP that stimulate insulin release), and dysregulation of glucagon secretion from pancreatic alpha cells, which further contributes to increased glucose output from the liver. ## Clinical Presentation T2DM often has an insidious onset, with many individuals remaining asymptomatic for years. When symptoms do appear, they are typically mild and non-specific. Common presentations include polyuria (frequent urination, especially at night), polydipsia (increased thirst), and polyphagia (increased hunger). Other symptoms may include fatigue, unexplained weight loss (though T2DM is more commonly associated with obesity), blurred vision (due to osmotic changes in the lens), slow-healing sores, and recurrent infections (e.g., skin infections, urinary tract infections, yeast infections). In the context of E11.9, these symptoms, if present, are typically mild, and there is no evidence of specific, chronic microvascular or macrovascular complications usually associated with prolonged, uncontrolled diabetes. ## Diagnostic Criteria Diagnosis of T2DM is based on blood glucose measurements. According to the American Diabetes Association (ADA), diabetes is diagnosed by any of the following criteria, ideally confirmed by a repeat test on a different day: * **Fasting Plasma Glucose (FPG):** ≥ 126 mg/dL (7.0 mmol/L) (fasting is defined as no caloric intake for at least 8 hours). * **2-hour Plasma Glucose during an Oral Glucose Tolerance Test (OGTT):** ≥ 200 mg/dL (11.1 mmol/L) after ingesting a 75-g glucose load. * **Hemoglobin A1c (HbA1c):** ≥ 6.5%. * **Random Plasma Glucose:** ≥ 200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis. Prediabetes, an intermediate state of glucose dysregulation, is diagnosed with FPG 100-125 mg/dL, 2-hour OGTT 140-199 mg/dL, or HbA1c 5.7-6.4%. ## Standard of Care The management of T2DM without complications primarily focuses on lifestyle modifications and pharmacological therapy to achieve glycemic control and prevent the development of complications. ### Lifestyle Modifications * **Dietary Changes:** Emphasis on a balanced diet rich in whole grains, fruits, vegetables, and lean proteins, with reduced intake of refined carbohydrates, added sugars, and unhealthy fats. Portion control is crucial. * **Regular Physical Activity:** At least 150 minutes per week of moderate-intensity aerobic exercise, coupled with resistance training on two or more days per week. * **Weight Management:** Achieving and maintaining a healthy weight through diet and exercise is fundamental, as even modest weight loss can significantly improve insulin sensitivity. ### Pharmacological Therapy * **Metformin:** Typically the first-line pharmacologic agent due to its efficacy, safety profile, and cardiovascular benefits. It primarily reduces hepatic glucose production and improves insulin sensitivity. * **Other Oral Agents:** If metformin alone is insufficient, other classes of medications may be added, including sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and thiazolidinediones. * **GLP-1 Receptor Agonists:** Injectable medications that enhance glucose-dependent insulin secretion, slow gastric emptying, and promote satiety. Many have demonstrated cardiovascular and renal benefits. * **Insulin Therapy:** May be initiated if other agents fail to achieve glycemic targets, or if the patient presents with severe hyperglycemia. ### Monitoring and Education Regular monitoring of blood glucose levels (both self-monitoring and HbA1c), blood pressure, lipid profiles, and kidney function is essential. Patient education regarding diet, exercise, medication adherence, and recognizing symptoms of hypoglycemia or hyperglycemia is crucial for successful long-term management and complication prevention.

Clinical Symptoms

  • Polyuria (frequent urination)
  • Polydipsia (increased thirst)
  • Polyphagia (increased hunger)
  • Fatigue
  • Unexplained weight loss (less common than in Type 1 but can occur)
  • Blurred vision (due to osmotic changes in the lens)
  • Slow-healing sores or cuts
  • Recurrent skin infections (e.g., boils, carbuncles)
  • Recurrent urinary tract infections
  • Yeast infections (e.g., candidiasis)
  • Acanthosis nigricans (darkening and thickening of skin, particularly in skin folds)

Common Causes

  • Insulin resistance (primary underlying factor)
  • Beta-cell dysfunction and progressive failure to produce sufficient insulin
  • Genetic predisposition and family history of Type 2 Diabetes
  • Obesity and overweight (especially central/abdominal obesity)
  • Physical inactivity and sedentary lifestyle
  • Unhealthy diet (high intake of refined carbohydrates, sugary drinks, saturated/trans fats)
  • Age (risk increases with age, typically after 45 years)
  • Ethnicity (higher prevalence in certain groups: African Americans, Hispanic/Latino Americans, American Indians, Asian Americans)
  • History of gestational diabetes
  • Polycystic Ovary Syndrome (PCOS)
  • Hypertension
  • Dyslipidemia (high triglycerides, low HDL cholesterol)
  • Certain medications (e.g., glucocorticoids, some antipsychotics, some diuretics)

Documentation & Coding Tips

Clearly document the type of diabetes, its chronic nature, and the current status of glycemic control. Specifically state the absence of complications if applicable, or document screenings for complications with negative results.

Example: Patient is a 62 YOM with long-standing Type 2 Diabetes Mellitus (T2DM), well-controlled on oral hypoglycemics. Current A1c 6.5%. No evidence of diabetic retinopathy, nephropathy, or neuropathy identified during today's comprehensive annual diabetic check. Foot exam reveals intact sensation, strong pulses, no ulcers or deformities. Renal function (eGFR 90, UACR <30) and eye exam (dilated funduscopy) performed within the last 3 months with normal findings. Continue metformin 1000mg BID. Patient educated on diet, exercise, and glucose monitoring.

Billing Focus: Documentation of 'Type 2 Diabetes Mellitus' (E11) and 'well-controlled' supports the diagnosis. Explicitly stating 'no evidence of complications' reinforces E11.0. Mentioning screening activities (foot exam, renal function, eye exam) supports the medical necessity for associated CPT codes.

Distinguish between controlled and uncontrolled diabetes. While E11.0 is for T2DM without complications, the control status is crucial for management and future coding decisions (though not explicitly part of the E11.0 code itself).

Example: 68 YOF with Type 2 Diabetes Mellitus, currently well-controlled with lifestyle modifications and glipizide. Fasting glucose consistently between 90-110 mg/dL. Patient reports adherence to diabetic diet and regular walking. Annual comprehensive foot exam and dilated eye exam negative for diabetic neuropathy or retinopathy. Microalbumin/creatinine ratio within normal limits. Continue current management. Patient to follow up in 3 months. No new complications identified.

Billing Focus: The phrase 'well-controlled' supports the accurate depiction of the patient's chronic condition. Even without complications, demonstrating active management and good control justifies higher-level E/M services for chronic disease management. Mentioning adherence reinforces patient engagement.

For patients with T2DM, always document the management plan, including medication changes, lifestyle advice, and referrals, even in the absence of complications. This supports medical necessity for follow-up visits.

Example: 55 YOM with newly diagnosed Type 2 Diabetes Mellitus. Started on Metformin 500mg daily. Patient educated extensively on carbohydrate counting, importance of daily physical activity, and home blood glucose monitoring (HBGM). Referred to diabetic education and nutritionist for further counseling. Initial labs (A1c 7.2%) do not show evidence of retinopathy or nephropathy based on recent retinal screening and normal eGFR. No neuropathy symptoms reported. Follow up in 6 weeks for medication titration and review of HBGM logs.

Billing Focus: Documentation of the detailed management plan (medication, education, referrals) supports the complexity of decision-making for a new diagnosis, justifying a higher E/M level. Stating 'no evidence of complications' confirms E11.0.

Regularly screen for and explicitly document the absence of common diabetic complications (retinopathy, nephropathy, neuropathy, peripheral vascular disease, foot ulcers). This reinforces E11.0 if negative and provides a baseline.

Example: 70 YOF with Type 2 Diabetes Mellitus for 15 years, currently managed with insulin detemir and insulin aspart. Comprehensive diabetic foot exam today: intact sensation with 10g monofilament test, strong dorsalis pedis and posterior tibial pulses bilaterally, no calluses or ulcerations. Review of recent labs: eGFR 65 mL/min/1.73m^2 with UACR 25 mg/g, considered stage 2 CKD related to age but not yet diagnostic of diabetic nephropathy per nephrology consultation. Ophthalmologic exam within 6 months reported 'no diabetic retinopathy'. Patient denies any neuropathic symptoms. Continue insulin regimen, monitor renal function annually. Instructed on daily foot checks.

Billing Focus: Explicitly documenting the findings of screenings ('intact sensation,' 'strong pulses,' 'no ulcerations,' 'no diabetic retinopathy,' 'UACR within normal limits for age-related CKD') clearly supports the 'without complications' aspect of E11.0. This documentation also justifies billing for comprehensive exams (e.g., diabetic foot exam components) and demonstrates the thoroughness of the visit.

Relevant CPT Codes

Related Diagnoses

Hierarchy